Singlera Genomics signed a research and distribution agreement with Pure Medical to commercialize its cell‑free DNA methylation assays—mTitan and mGuard—across several Western European countries. The companies will also collaborate with universities, hospital networks, and national health systems on research studies. Singlera’s platforms screen circulating cfDNA methylation haplotypes linked to multiple tumor types, and the deal aims to bring lower‑cost early cancer detection and monitoring tools to European clinicians. Singlera also recently announced a research collaboration with the University of Pittsburgh to explore its BT‑Reveal pancreatic cancer test. The agreement reflects growing demand in Europe for accessible, methylation‑based liquid biopsies and could accelerate local validation studies needed for clinical adoption and reimbursement.